PMID- 23098345
OWN - NLM
STAT- MEDLINE
DCOM- 20130226
LR  - 20181202
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 52
IP  - 10
DP  - 2012
TI  - [Acute non ST-elevation coronary syndrome in real practice of hospitals in 
      Russia. Comparative data from RECORD 2 and RECORD registries].
PG  - 9-16
AB  - AIM: to compare data on pre- and in hospital treatment of non ST-elevation (NSTE) 
      acute coronary syndromes (ACS) in Russian ACS registers RECORD (recruitment from 
      11.2007 to 02.2008) and RECORD-2 (from 04/2009 to 04.2011). MATERIAL: Four of 7 
      hospitals participating in RECORD-2 were invasive (57.1% vs. 55.6% in RECORD). In 
      RECORD-2 10-30 consecutive patients with NSTEACS were included monthly in each 
      center; recruitment in RECORD was described elsewhere. RESULTS: Mean age of 
      patients was similar in two registries. Portion of women was significantly higher 
      in RECORD-2 (42.9% vs. 26.0% in RECORD; <0.0001). Although markers of necrosis 
      were measured in higher proportion of patients in RECORD-2, frequency of troponin 
      determination was not significantly different (47.0 vs. 43.5% in RECORD; =0.64). 
      Patients in RECORD-2 more frequently received prehospital aspirin (51.6 vs 33.5%; 
      <0.0001), aspirin in recommended initial dose 160-325 mg (64.3 vs. 47.1%; =0.03), 
      and clopidogrel during hospitalization (47.0 vs. 27.6%; <0.0001). Rates of in 
      hospital use of parenteral anticoagulants in both registries were similar, but 
      among anticoagulants in RECORD 2 proportion of fondaparinucs became noticeable 
      (9.5%) and that of low molecular weight heparin (LMWH) became significantly 
      higher (21.2 vs. 11.6% in RECORD). Almost one third of patients in RECORD-2 who 
      were treated with unfractionated heparin (UFH) received it subcutaneously. About 
      half of patients treated with intravenous infusion of UFH received it for less 
      than 48 hours. Although higher proportion of patients hospitalized in invasive 
      hospitals were subjected to diagnostic coronary angiography in RECORD-2 (80.8 vs. 
      54.3% in RECORD; <0.0001) differences between registries in rates of percutaneous 
      coronary interventions (PCI) (all - 37.3 vs. 29.9%; =0.051; first 72 hours - 22.7 
      vs. 24.8%; =0.55), and coronary artery bypass graftings (5.6 vs. 5.8%; =0.12) 
      were not significant. There were no significant differences in rates of any in 
      hospital unfavorable events. Analysis of treatment and outcomes in groups of high 
      risk patients (GRACE score >140) gave results close to those in all patients 
      except mortality which was statistically similar but numerically higher in 
      RECORD-2 (9.3 vs. 7.9% in RECORD; p=0.68). CONCLUSION: Comparison of data of 2 
      limited NSTEACS registers conducted with interval of about 2 years showed only 
      modest shift towards fulfillment of contemporary recommendations which was not 
      associated with increase in rates of PCI and improvement of outcomes especially 
      in high risk patients.
FAU - Erlikh, A D
AU  - Erlikh AD
FAU - Gratsianskii, N A
AU  - Gratsianskii NA
LA  - rus
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - Acute Coronary Syndrome/diagnosis/*epidemiology/therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage
MH  - Clopidogrel
MH  - Coronary Angiography
MH  - *Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heparin, Low-Molecular-Weight/*administration & dosage
MH  - Hospital Mortality/trends
MH  - Hospitals/*statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - *Registries
MH  - Retrospective Studies
MH  - Russia/epidemiology
MH  - Survival Rate/trends
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/10/27 06:00
MHDA- 2013/02/27 06:00
CRDT- 2012/10/27 06:00
PHST- 2012/10/27 06:00 [entrez]
PHST- 2012/10/27 06:00 [pubmed]
PHST- 2013/02/27 06:00 [medline]
PST - ppublish
SO  - Kardiologiia. 2012;52(10):9-16.